States that researchers report two successful methods of battling hairy cell leukemia, a rare cancer of white blood cells. Study by Lawrence D. Piro and his colleagues at the Scripps Clinic and Research Foundation in La Jolla, California; Research by Michael R. Grever of the National Cancer ...
New treatments for acute myeloid leukemia: how much has changed?doi:10.1038/s41375-020-01084-2Elihu EsteyLeukemia
The first comprehensive computer model to simulate the development of blood cells could help in the development of new treatments forleukemia(opens in new tab)andlymphoma(opens in new tab), say researchers at the University of Cambridge and Microsoft Research. ...
Acute myeloid leukemia (AML) also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.
The prognosis for the T-ALL form of leukemia when relapsed is very poor, and new treatments are urgently required. The new therapy developed by the two institutions is a combination of drugs which was found to be effective in approximately one-third of patients. ...
Acute myelogenous leukemia (AML) is a rapidly progressive form of blood cancer that arises from immature myeloid cells. Traditional treatments, such as chemotherapy and bone marrow transplants, have had limited success in treating the disease, necessitating the development of novel therapeutic strategies...
Treatments for acute lymphoblastic leukemia (ALL) are improving as the overall survival rate at five years from diagnosis raised from 12% in 1960 to 65% in 2014 and around 80% nowadays (1). Unfortunately, in the case of T-cell Acute Lymphoblastic Leukemia (T-ALL), an aggressive subtype of...
"Therapy for acute myeloid leukemia has barely changed in several decades. There is a huge need to discover better treatments for this aggressive disease. We've shown for the first time that targeting the pathways that our cells use to respond to oxygen levels could provide a new way to trea...
The Canadian team demonstrated that leukemia cells have unique energy requirements and it is possible to selectively shut down thisenergy productionin leukemia cells by blocking protein synthesis in the mitochondria. By looking for new treatments in approved drugs, cancer researchers may be able to rap...
which is why venetoclax also specifically eliminatescancer cellsin this form of leukaemia. Another advantage is that, in contrast to chemotherapy, treatment with thisdrugonly causes minimal side-effects in patients. Moreover, two T-PLL patients, who did not respond to other standard treatments, hav...